Is Protagonist Therapeutics Inc (PTGX) a risky stock?
As of July 27, 2026, Clavix grades Protagonist Therapeutics Inc (PTGX) B- for risk, a composite score of 70 out of 100 on an A+ to F scale, which puts PTGX in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 27, 2026. Clavix regrades every trading day.
The five risk dimensions behind PTGX's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how PTGX scores on each, as of July 27, 2026.
What's moving PTGX's risk right now
Company-specific signals Clavix flags behind PTGX's current grade, drawn from recent news and filings as of July 27, 2026.
A new institutional investor has taken a significant ~$24.5 million position in PTGX, signaling growing institutional confidence in the company and adding a notable holder to its…
A major institutional investor more than tripled its position in PTGX, signaling strong institutional confidence in the stock and potentially providing price support through incre…
Recent PTGX news
The latest headlines Clavix ingested for Protagonist Therapeutics Inc, newest first. These feed the news-sentiment dimension of PTGX's grade.
-
Wall Street Zen upgraded Protagonist Therapeutics (NASDAQ:PTGX) from a 'buy' to a 'strong-buy' rating in a research report issued on Saturday.
What a B- grade means
On the Clavix A+ to F scale, PTGX's composite of 70 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell PTGX or any security. Grades are risk indicators, not predictions of return. Data may be delayed.